iPhone 17 Demand Lifts AAPL Supercycle, AI & Innovation "Question Mark" — Positive
AAPL Schwab Network — January 09, 2026The holiday season added muscle to Apple's (AAPL) iPhone 17 sales. @LikeFolio's data shows strong demand in the tail-end of 2025, something Megan Brantley believes offers a good set-up for 2026.
Toll Brothers Announces the Release of New Ranch Home Designs at Aurora Ridge at Great Sky in Canton, Georgia — Neutral
TOL GlobeNewsWire — January 09, 2026CANTON, Ga., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced the release of two new home designs at Aurora Ridge at Great Sky, a premier community by Toll Brothers in the scenic hills of Cherokee County, Georgia.
Deadline Soon: Stride, Inc. (LRN) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit — Neutral
LRN Business Wire — January 09, 2026LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 12, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN) securities between October 22, 2024 and October 28, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON STRIDE, INC. (LRN), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD.
Olin Corporation remains a "Buy" as shares trade at a compressed ~9x mid-cycle earnings, despite recent operational setbacks. The Q4 EBITDA miss is primarily due to one-time maintenance overruns at Freeport; operations have since normalized, but capex may need to rise to sustainable levels. Demand headwinds persist, especially from weak Chinese and U.S. construction, with 2026 results expected to be flat or slightly lower versus 2025.
3 Reasons Why You Should Keep Owning Realty Income In 2026 — Positive
O Seeking Alpha — January 09, 2026Realty Income offers a highly diversified, resilient tenant portfolio across 92 industries, limiting exposure to any single client or sector. O maintains a 5.6% yield with a strong history of monthly dividend growth, supported by robust AFFO and FFO performance. Valuation models indicate O's fair value is $63–$71.5 per share, implying 11%–25% upside from current levels.
Here's Why Investors Should Retain Euronet Stock for Now — Positive
EEFT Zacks Investment Research — January 09, 2026EEFT's transaction growth, global expansion, acquisitions and digital payment push support its long-term outlook despite recent share declines.
Visa's Tokenization Push Is Becoming More Than a Security Play — Positive
V Zacks Investment Research — January 09, 2026V's tokenization push is evolving beyond security, boosting transaction efficiency, AI-driven insights and seamless payments across devices.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Varonis Systems, Inc. (VRNS) Shareholders To Inquire About Securities Fraud Class Action — Neutral
VRNS Business Wire — January 09, 2026LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Varonis Systems, Inc. (“Varonis” or the “Company”) (NASDAQ: VRNS) common stock between February 4, 2025 and October 28, 2025, inclusive (the “Class Period”). Varonis investors have until March 9, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON.
Nashville's Anzie Blue and Honda Powersports Wrap 2025 With Global New Year's Eve, Star-studded Musical Event Highlighting the Best of Music City — Neutral
HMC Business Wire — January 09, 2026NASHVILLE, Tenn.--(BUSINESS WIRE)--The spirit of Music City was on full display on New Year's Eve as indie music venue Anzie Blue and Honda Powersports partnered to present Anzie Blue New Year's Eve Live, a first-time musical event featuring a genre-spanning lineup that was seen worldwide. The six-hour event was livestreamed on CNN.com, with select performances airing live on CNN as part of its daytime coverage of New Year's Eve from cities around the world. Hosted by CNN anchor Lynda Kinkade,.
Deadline Soon: Freeport-McMoran Inc. (FCX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit — Neutral
FCX Business Wire — January 09, 2026LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 12, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Freeport-McMoran Inc. (“Freeport” or the “Company”) (NYSE: FCX) securities between February 15, 2022 and September 24, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON FREEPORT-MCMORAN INC. (FCX), CLICK HERE TO PARTICIPATE I.
UPDATE - OHA Leads Private Debt Financing Supporting Majesco's Acquisition of Vitech — Neutral
TROW GlobeNewsWire — January 09, 2026New York, New York, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oak Hill Advisors (“OHA”) served as Administrative Agent and Lead Left Arranger for a private unitranche financing supporting Majesco's acquisition of Vitech Systems Group (“Vitech”) and a concurrent refinancing. Majesco, a portfolio company of Thoma Bravo, is a leading provider of cloud-native, AI-native software for insurers in the property and casualty (P&C) and life, annuity and health (L&AH) sectors. Vitech is a complementary provider of cloud-native pension and benefits administration software.
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology — Positive
JAZZ Seeking Alpha — January 09, 2026Jazz Pharmaceuticals plc is deeply undervalued, trading at 2.4x sales, as the market overlooks its oncology pivot and robust growth catalysts. Ziihera's Phase 3 data surpassing Herceptin signals a transformative 'pipeline in a product' opportunity, targeting multi-billion-dollar HER2+ cancer market. Zepzelca's expanded front-line SCLC approval and Epidiolex's blockbuster trajectory underpin near-term revenue growth and portfolio diversification.
USA Rare Earth Crosses 50-Day SMA: Should You Buy the Stock Now? — Positive
USAR Zacks Investment Research — January 09, 2026USAR crosses its 50-day SMA as shares climb 52% in six months, with Stillwater magnet plant advances and a $400M cash boost driving momentum.
Pagaya Shines in 2025: How Should Investors Play the Fintech Stock? — Positive
PGY Zacks Investment Research — January 09, 2026PGY hit a 2025 inflection point with three straight GAAP profits, shrinking credit losses and a 125% share surge amid stronger fundamentals.
RPM Q2 Earnings & Sales Miss Estimates, Adjusted EBIT Down Y/Y — Negative
RPM Zacks Investment Research — January 09, 2026RPM International posts a Q2 earnings and sales miss as costs pressure margins, though acquisitions lift revenues and management sees improvement ahead.
Looking for a Growth Stock? 3 Reasons Why Commercial Metals (CMC) is a Solid Choice — Positive
CMC Zacks Investment Research — January 09, 2026Commercial Metals (CMC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Roundup: Is Everything Priced In But Normalcy? — Neutral
BAC C CAT DAL GS HAL IIPR JBHT META MU OKLO RBLX SNDK VST WFC Seeking Alpha — January 09, 2026AI-driven demand is fueling outsized gains in memory, storage, and power infrastructure stocks, with SNDK up 71% in a month and MU up 230% in 2025. Geopolitical events, notably US action in Venezuela, boosted oil and defense stocks, but pressured Canadian oil sands due to heavy crude competition.
Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial — Neutral
ASRT Business Wire — January 09, 2026LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an e.
Deadline Alert: DeFi Technologies Inc. (DEFT) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit — Neutral
DEFT GlobeNewsWire — January 09, 2026LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming January 30, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired DeFi Technologies Inc. (“DeFi” or the “Company”) (NASDAQ: DEFT) securities between May 12, 2025 and November 14, 2025, inclusive (the “Class Period”).
3 Tech Stocks Positioned for the Next Leg of the Bull Market — Positive
AVGO ORCL UBER MarketBeat — January 09, 2026The first few trading days of January have reminded investors that we're still operating in a manic market. Each of the major indexes has closed at a new all-time high in January, and as of the market opening on Jan. 8, all the indexes were positive for the year.